Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H41N3O5 |
| Molecular Weight | 523.6636 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC3=C(N(CCCOC(=O)C(C)(C)C)C=C3)C(=C2)C(N)=O
InChI
InChIKey=CTMYLDUPTAZFCT-OAQYLSRUSA-N
InChI=1S/C30H41N3O5/c1-6-36-25-10-7-8-11-26(25)37-17-13-32-21(2)18-22-19-23-12-15-33(27(23)24(20-22)28(31)34)14-9-16-38-29(35)30(3,4)5/h7-8,10-12,15,19-21,32H,6,9,13-14,16-18H2,1-5H3,(H2,31,34)/t21-/m1/s1
| Molecular Formula | C30H41N3O5 |
| Molecular Weight | 523.6636 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:16:36 GMT 2023
by
admin
on
Sat Dec 16 10:16:36 GMT 2023
|
| Record UNII |
9529MK8HWG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9529MK8HWG
Created by
admin on Sat Dec 16 10:16:36 GMT 2023 , Edited by admin on Sat Dec 16 10:16:36 GMT 2023
|
PRIMARY | |||
|
9872508
Created by
admin on Sat Dec 16 10:16:36 GMT 2023 , Edited by admin on Sat Dec 16 10:16:36 GMT 2023
|
PRIMARY | |||
|
KRG-3332(FREE BASE)
Created by
admin on Sat Dec 16 10:16:36 GMT 2023 , Edited by admin on Sat Dec 16 10:16:36 GMT 2023
|
PRIMARY | Originator: Kissei Pharmaceutical; Class: Antiglaucomas; Mechanism of Action: Alpha 1a adrenergic-receptor antagonists; Highest Development Phase: Discontinued for Glaucoma use | ||
|
239463-68-4
Created by
admin on Sat Dec 16 10:16:36 GMT 2023 , Edited by admin on Sat Dec 16 10:16:36 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
The companies say that the new compound is a highly-selective alpha-1A receptor antagonist, administered as an eye-drop which is expected to lower intraocular pressure in glaucoma patients by facilitating the outflow of fluid from the eye. Pharmacological studies in animals have shown that this efficacy is well-maintained over time.
|
||
|
ACTIVE MOIETY |
Novartis Ophthalmics last week announced that it had entered a license option agreement with Kissei Pharmaceutical Co. Ltd. for new glaucoma agent KRG-3332, a highly selective alpha 1A receptor. Studies in animals show the agent successfully reduces intraocular pressure and that efficacy is well-maintained over time.
|
